AZD7762: The Future of Cancer Therapy? #sciencefather #AZD7762

AZD7762 is a potent checkpoint kinase 1 (Chk1) inhibitor designed to enhance the efficacy of DNA-damaging therapies like chemotherapy and radiation by disrupting cancer cells' ability to repair DNA. By inhibiting Chk1, AZD7762 abrogates the G2/M cell cycle checkpoint, leading to increased DNA damage, mitotic catastrophe, and apoptosis in tumor cells. Preclinical studies have demonstrated its potential in sensitizing various cancers—including triple-negative breast cancer, urothelial carcinoma, osteosarcoma, and pancreatic cancer—to agents like gemcitabine, cisplatin, and radiation . Visit Our Website : http://biotechnologyscientist.com Contact Us : support@biotechnologyscientist.com Nomination Link : https://biotechnologyscientist.com/award-nomination/?ecategory=Awards&rcategory=Awardee #AZD7762 #Chk1Inhibitor #CancerTherapy #DNARepair #MitoticCatastrophe #TripleNegativeBreastCancer #UrothelialCarcinoma #Osteosarcoma #PancreaticCancer #Gemcitabine #Cisplatin #RadiationTherapy #CellCycleCheckpoint #Apoptosis #Cardiotoxicity #BAG3 #TargetedTherapy #OncologyResearch #PrecisionMedicine #ClinicalTrials